BFC
INDP icon

Bedel Financial Consulting’s Indaptus Therapeutics INDP Stock Holding History

Bedel Financial Consulting’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4
Closed -$3K – 852
2020
Q3 		$3K Buy
+4
New +$2.94K ﹤0.01% 677

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HAG
HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bedel Financial Consulting's INDP Position: Q4 2020 in Review

Bedel Financial Consulting sold out of Indaptus Therapeutics (INDP) in Q4 2020, closing a stake of 4 shares — an estimated $3K sold.

Bedel Financial Consulting first reported a position in INDP in Q3 2020 and held it in 1 quarter. The position peaked at $3K in Q3 2020. 18 funds tracked by Wall St. Rank hold INDP as of Q4 2020.

  • Bedel Financial Consulting reported no remaining Indaptus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Bedel Financial Consulting sold 4 Indaptus Therapeutics shares in Q4 2020, an estimated $3K.
  • Bedel Financial Consulting first reported a position in Indaptus Therapeutics in Q3 2020 and held it in 1 quarter.
  • Bedel Financial Consulting's Indaptus Therapeutics position peaked at $3K in Q3 2020.
  • 18 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2020.

Based on Bedel Financial Consulting's 13F filing for Q4 2020, filed 2 Feb 2021.